The MedTech M&A landscape experienced a second consecutive year of decline in 2023, witnessing reduced deal volumes compared to previous years. The focus among companies shifted towards smaller, tuck-in acquisitions during this period. Despite the subdued activity in 2023, indications suggest a resurgence in MedTech M&A in 2024, driven by the industry's imperative to grow and adapt to the evolving healthcare environment.